Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Single-Arm, Open-label, Multicenter Study Evaluating the Efficacy of Adjunctive Zanubrutinib and CAR T-Cell Therapy in Aggressive B-Cell Non-Hodgkin's Lymphoma

NCT05202782 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT05202782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05202782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Single-Arm, Open-label, Multicenter Study Evaluating the Efficacy of Adjunctive Zanubrutinib and CAR T-Cell Therapy in Aggressive B-Cell Non-Hodgkin's Lymphoma
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 21, 2022
Completion date
October 9, 2029
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma associated with chronic inflammation, ebv-positive diffuse large b-cell lymphoma, not otherwise specified, high grade b-cell lymphoma, not otherwise specified, large b-cell lymphoma with irf4 rearrangement, primary cutaneous diffuse large b-cell lymphoma, leg type, recurrent aggressive b-cell non-hodgkin lymphoma, recurrent diffuse large b-cell lymphoma, not otherwise specified, recurrent high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, recurrent intravascular large b-cell lymphoma, recurrent primary mediastinal (thymic) large b-cell lymphoma, recurrent t-cell/histiocyte-rich large b-cell lymphoma, recurrent transformed b-cell non-hodgkin lymphoma, refractory aggressive b-cell non-hodgkin lymphoma, refractory diffuse large b-cell lymphoma, not otherwise specified, refractory high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, refractory intravascular large b-cell lymphoma, refractory primary mediastinal (thymic) large b-cell lymphoma, refractory t-cell/histiocyte-rich large b-cell lymphoma, refractory transformed b-cell non-hodgkin lymphoma